Future Directions in the Management of Non-melanoma Skin Cancer

  • Gerard Adams
  • Sandro V. Porceddu
Part of the Head and Neck Cancer Clinics book series (HNCC)


The current and future management of non-melanoma skin cancer (NMSC)—predominantly basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)—represents a significant public health problem worldwide. Australia has one of the highest rates of skin cancer in the world, with data showing that NMSC is five times more common than all other cancers combined [1]. The sun-exposed head and neck (HN) is the most common location, with incidence rates continuing to rise 3–10 % per year. Although BCC is more common, the vast majority of NMSCs are localized and easily treated with simple excision. However, 5 % are considered high-risk (nearly always SCC) and metastasize to regional lymph nodes with the potential for distant spread [2].


Neck Dissection Basal Cell Carcinoma Merkel Cell Carcinoma Epithelial Growth Factor Receptor Basal Cell Nevus Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Staples MP, Elwood E, Burton RC, et al. Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med J Aust. 2006;184:6–10.PubMedGoogle Scholar
  2. 2.
    Alam M, Ratner D. Cutaneous squamous cell carcinoma. N Engl J Med. 2001;344:975–83.CrossRefPubMedGoogle Scholar
  3. 3.
    Schollkopf C, Rosendahl D, Rostgaard K, et al. Risk of second cancer after chronic lymphocytic leukemia. Int J Cancer. 2007;121:151–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Cooksley CD, Hwang LY, Waller DK, et al. HIV-related malignancies: community-based study using linkage of cancer registry and HIV registry data. Int J STD AIDS. 1999;10:795–802.CrossRefPubMedGoogle Scholar
  5. 5.
    Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40:177–86.CrossRefPubMedGoogle Scholar
  6. 6.
    Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64:1421–6.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Australian Institute of Health and Welfare (AIHW). Health system expenditures on cancer and other neoplasms in Australia 2000–2001. AIHW cat. no. HWE 29. Health and Welfare Expenditure Series No. 22. Canberra: Australian Institute of Health and Welfare; 2005.Google Scholar
  8. 8.
    Oddone N, Gary J, Morgan GJ, et al. Metastatic cutaneous squamous cell carcinoma of the head and neck. The Immunosuppression, Treatment, Extranodal Spread, and Margin Status (ITEM) Prognostic Score to Predict Outcome and the Need to Improve Survival. Cancer. 2009;115:1883–91.CrossRefPubMedGoogle Scholar
  9. 9.
    Veness MJ, Porceddu S, Palme CE, et al. Cutaneous head and neck squamous cell carcinoma metastatic to parotid and cervical lymph nodes. Head Neck. 2007;29:621–31.CrossRefPubMedGoogle Scholar
  10. 10.
    Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–44.CrossRefPubMedGoogle Scholar
  11. 11.
    Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945–52.CrossRefPubMedGoogle Scholar
  12. 12.
    Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999;22:32–4.CrossRefPubMedGoogle Scholar
  13. 13.
    Sadek H, Azli N, Wendling JL, et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil and bleomycin. Cancer. 1990;66:1692–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Porceddu SV, Campbell B, Rischin D, et al. Postoperative chemo-radiotherapy for high-risk head and neck squamous cell carcinoma (HNSCC). Int J Radiat Oncol Biol Phys. 2004;60:365–73.CrossRefPubMedGoogle Scholar
  15. 15.
    O’Hara J, Ferlito A, Takes RP, Rinaldo A, et al. Cutaneous squamous cell carcinoma of the head and neck metastasizing to the parotid gland – a review of current recommendations. Head Neck. 2011;33:1789–95.CrossRefPubMedGoogle Scholar
  16. 16.
    Kirke DN, Porceddu S, Wallwork BD, et al. Pathologic occult neck disease in patients with metastatic cutaneous squamous cell carcinoma to the parotid. Otolaryngol Head Neck Surg. 2011;144:549–51.CrossRefPubMedGoogle Scholar
  17. 17.
    Audet N, Palme CE, Gullane PJ, et al. Cutaneous metastatic squamous cell carcinoma to the parotid gland: analysis and outcome. Head Neck. 2004;26:727–32.CrossRefPubMedGoogle Scholar
  18. 18.
    Dona E, Veness MJ, Cakir B, et al. Metastatic cutaneous squamous cell carcinoma to the parotid: the role of surgery and adjuvant radiotherapy to achieve best outcome. ANZ J Surg. 2003;73:692–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Ying YM, Johnson JT, Myers EN. Squamous cell carcinoma of the parotid gland. Head Neck. 2006;28:626–32.CrossRefPubMedGoogle Scholar
  20. 20.
    O’Brien CJ, McNeil EB, McMahon JD, et al. Incidence of cervical node involvement in metastatic cutaneous malignancy involving the parotid gland. Head Neck. 2001;23:744–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Machtay M, Moughan M, Trotti T, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008;26:3582–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Donatelli-Lassig AA, Duffy SA, Fowler KE, et al. The effect of neck dissection on quality of life after chemoradiation. Otolaryngol Head Neck Surg. 2008;139:511–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Panizza B, Solares CA, Redmond M, et al. Surgical resection for clinical perineural invasion from cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2012;34:1622–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Gandhi MR, Panizza B, Kennedy D. Detecting and defining the anatomic extent of large nerve perinerual spread of malignancy: comparing ‘targeted MRI’ with the historic findings following surgery. Head Neck. 2011;33:469–75.CrossRefPubMedGoogle Scholar
  25. 25.
    Barnett CM, Foote MC, Panizza B. Cutaneous head and neck malignancies with perineural spread to contralateral cranial nerves: an argument for extending postoperative radiotherapy volume. J Clin Oncol. 2013;31:2291–3.CrossRefGoogle Scholar
  26. 26.
    Bischoff EPE. Microscopic analysis of the anastamosis between the cranial nerves. Hanover: University Press of New England; 1997. p. 1–138.Google Scholar
  27. 27.
    Myckatyn TM, Mackinnon SE. A review of facial nerve anatomy. Semin Plast Surg. 2004;18:5–12.PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    Ballantyne AJ, McCarten AB, Ibanez ML. The extension of cancer of the head and neck through peripheral nerves. Am J Surg. 1963;106:651–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Grégoire V, Levendag P. CT-based delineation of lymph node levels in the N0 neck: DAHANCA, EORTC, GORTEC, RTOG consensus guidelines. Accessed 16 June 2013.
  30. 30.
    Scott AM, Gunawardana DH, Bartholomeusz D, et al. PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a multicenter prospective study. J Nucl Med. 2008;49:1593–600.CrossRefPubMedGoogle Scholar
  31. 31.
    Wagner JD, Schauwecker DS, Davidson D, et al. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol. 2001;77:237–42.CrossRefPubMedGoogle Scholar
  32. 32.
    Boswell JS, Flam MS, Tashjian DN, et al. Basal cell carcinoma metastatic to cervical lymph nodes and lungs. Dermatol Online J. 2006;12:9.PubMedGoogle Scholar
  33. 33.
    Cho SB, Chung WG, Yun M, et al. Fluorodeoxyglucose positron emission tomography in cutaneous squamous cell carcinoma: retrospective analysis of 12 patients. Dermatol Surg. 2005;31:442–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Merkel PET Phase II ‘MP3’ Study (NCT01013779). Accessed 16 June 2013.
  35. 35.
    Nottage M, Francesconi A, Houston K, et al. A prospective study investigating the impact of definitive chemoradiation in locoregionally advanced squamous cell carcinoma of the skin. J Clin Oncol. 2012;30(suppl; abstr 8538).Google Scholar
  36. 36.
    Maubec E, Petrow P, Duvillard P, et al. Cetuximab as first-line monotherapy in patients with skin unresectable squamous cell carcinoma: final results of a phase II multicenter study. J Clin Oncol. 2010;28(suppl; abstr 8510).Google Scholar
  37. 37.
    Weber RS, Lustig RA, El-Naggar AK, et al. Gefitinib for advanced cutaneous squamous cell carcinoma of head and neck: phase II trial. J Clin Oncol. 2009;27(suppl; abstr 6054).Google Scholar
  38. 38.
    Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal cell carcinoma. N Engl J Med. 2009;361:1164–72.CrossRefGoogle Scholar
  39. 39.
    Cirrone F, Harris CS. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma. Clin Ther. 2012;34:2039–50.CrossRefPubMedGoogle Scholar
  40. 40.
    Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal cell nevus syndrome. N Engl J Med. 2012;366:2180–8.PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Atwood SX, Mischa L, Lee A, et al. GLI activation by atypical protein kinase Cι/λ regulates the growth of basal cell carcinomas. Nature. 2013;494:484–90.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Faruque Riffat, Carsten E. Palme, Michael Veness, Rehan Kazi, Raghav C. Dwivedi 2015

Authors and Affiliations

  1. 1.Radiation Oncology, Oceania Oncology BundabergBundabergAustralia
  2. 2.School of MedicineUniversity of QueenslandSt LuciaAustralia
  3. 3.Radiation OncologyUniversity of QueenslandSt LuciaAustralia
  4. 4.Princess Alexandra HospitalBrisbaneAustralia

Personalised recommendations